Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and William Ackman’s hedge fund Pershing Square Capital Management reportedly agreed to split litigation costs in a class action lawsuit brought on by shareholders over an alleged insider trading scheme in Allergan (NYSE:AGN)’s 2014 takeover bid. In June 2014, Valeant offered a tender bid for Allergan, which was followed by a 7 month-long […]
Allergan pays $15m for failing to disclose Actavis ‘white knight’ offer
The SEC said yesterday that Allergan (NYSE:AGN) will pay a $15 million fine for failing to disclose its 2014 merger talks with Actavis. In June 2014, Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) offered a tender bid for the Irvine, Calif.-based company which was followed by a 7 month-long hostile pursuit by Valeant and co-bidder Pershing Square Capital Management. In November […]
Valeant, Ackman can’t dodge insider trading case from failed Allergan takeover
(Reuters) — A U.S. judge said Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in Allergan (NYSE: AGN) before making an unsuccessful takeover bid for the maker of Botox. In a Nov. 9 decision, U.S. District Judge David Carter in Santa Ana, Calif., […]
Report: Actavis to lay off 577 at Allergan
CRM: BSX’s gain is STJ’s loss | Medtech Wall Street news for the week of March 23, 2015
ZMH set to acquire EU approval for $13B Biomet deal | The week in medtech M&A
Philips mulls 2016 IPO for lighting biz as bidding war heats up
J&J deals Cordis for nearly $2B | The week in medtech M&A
CAH top suitor for JNJ’s Cordis unit | The week in medtech M&A
Allergan name to live on post Actavis merger
